EG-018, a synthetic cannabinoid rooted in the carbazole structure, has found a niche in online markets as a designer drug. This compound is a partial agonist for CB1 and CB2 receptors, exhibiting a notably robust binding affinity. However, its effectiveness in eliciting a signaling response still needs to be higher.

IUPAC name
CAS Number2219320-91-7
PubChem CID118796466
Chemical and physical data
Molar mass391.514 g·mol−1

Legal status

EG-018 is a controlled substance in Japan.


1. What is EG-018?

  • EG-018 is a synthetic cannabinoid compound with its origins in the carbazole structure. It has gained attention as a designer drug.

2. Is EG-018 Legal?

  • The legal status of EG-018 varies by country and region. Its classification as a controlled substance may change over time. Always check your local regulations.

3. How Does EG-018 Affect CB1 and CB2 Receptors?

  • EG-018 acts as a partial agonist for both CB1 and CB2 receptors, with a strong binding affinity. However, it has a relatively low efficacy in inducing a signaling response.

4. What Are the Potential Effects of EG-018?

  • The effects of EG-018 may vary and can include alterations in mood and perception. Due to its synthetic nature, it may have unpredictable and potentially harmful effects.

5. Is EG-018 Safe to Use?

  • The safety of EG-018 is a subject of concern due to its limited research and the potential for adverse effects. Its use should be cautiously approached, and consulting a healthcare professional is advisable.

6. Can EG-018 Cause Addiction?

  • As with many synthetic cannabinoids, EG-018 may have addictive potential. Using it irresponsibly or in excessive amounts can increase the risk of addiction.

7. Where Can I Obtain EG-018 for Research or Recreational Purposes?

  • Access to EG-018 may be restricted in many regions. For research purposes, you should adhere to local laws and regulations. However, it is crucial to emphasize that the use of designer drugs for recreational purposes can be illegal and dangerous.

8. What Are the Risks of Using Designer Drugs Like EG-018?

  • Designer drugs like EG-018 can pose significant risks to health and safety. The lack of regulatory oversight means users may not know exactly what they are ingesting, leading to unpredictable and potentially harmful effects.

9. Is EG-018 the Same as Natural Cannabis?

  • No, EG-018 is a synthetic compound designed to interact with cannabinoid receptors, whereas natural cannabis contains a mix of cannabinoids with distinct properties.

10. Where Can I Find Reliable Information About EG-018?

  • Stay informed through reputable sources, scientific publications, and local authorities. Always consult with experts in the field and adhere to the laws and regulations of your region when it comes to researching or using substances like EG-018. Your safety and well-being should be a top priority.


  1. Explore the world of EG-018 at Cayman Chemical’s website for valuable insights into this synthetic cannabinoid.
  2. Mogler L, Franz F, Wilde M, Huppertz LM, Halter S, Angerer V, et al. (September 2018). “Delving into Phase I Metabolism: Unraveling the Intricacies of Carbazole-Derived Synthetic Cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA, Including Their Detection in Human Urine Samples.” Published in Drug Testing and Analysis, 10(9), 1417–1429. doi:10.1002/dta.2398. PMID: 29726116.
  3. Banister SD, Connor M (August 2018). “Synthetic Cannabinoid Receptor Agonists: The Chemistry and Pharmacology of New Psychoactive Substances – An Evolutionary Perspective.” Part of the “Handbook of Experimental Pharmacology” series, Volume 252, by Springer International Publishing, offering a comprehensive view of the subject. doi:10.1007/164_2018_144. ISBN: 978-3-030-10561-7. PMID: 30105473 – available via Springer Link.
  4. Gaunitz F, Dahm P, Mogler L, Thomas A, Thevis M, Mercer-Chalmers-Bender K (June 2019). “Understanding Synthetic Cannabinoids: In Vitro Metabolic Profiling and Detection in Urine Samples Using Pooled Human Liver Microsomes, Cytochrome P450 Isoenzymes, and Cunninghamella elegans.” Featured in Analytical and Bioanalytical Chemistry, 411(16), 3561–3579. doi:10.1007/s00216-019-01837-8. PMID: 31183523. S2CID 184487406.
  5. Diao X, Carlier J, Zhu M, Huestis MA (July 2018). “EG-018 Metabolism Unveiled: A Study in Human Hepatocytes Employing High-Resolution Mass Spectrometry.” Available in Forensic Toxicology, 36(2), 304–312. doi:10.1007/s11419-018-0404-2. ISSN: 1860-8973. S2CID 44196013.
  6. Gamage TF, Barrus DG, Kevin RC, Finlay DB, Lefever TW, Patel PR, et al. (June 2020). “Pharmacological Evaluation of EG-018: A Synthetic Cannabinoid Receptor Agonist – Insights from In Vitro and In Vivo Studies.” Detailed in Pharmacology, Biochemistry, and Behavior, 193, 172918. doi:10.1016/j.pbb.2020.172918. PMC: 7239729. PMID: 32247816.
  7. “指定薬物を指定する省令が公布されました|厚生労働省” [Announcement of Cabinet Order Designating Specific Drugs]. Published on the Ministry of Health, Labour and Welfare website (in Japanese) – Providing information on regulatory actions related to EG-018.

Leave a Comment

Your email address will not be published. Required fields are marked *